A gigantic bulge in the north rim of the Yellowstone caldera is the latest sign of volcanic activity in the national park.
The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since being founded last year, Caldera has already taken the therapy, dubbed CLD-423, ...
Scientists are monitoring a city of Chicago-sized swath of rising ground at the northern volcanic rim of the Yellowstone ...
Yellowstone is a dynamic geologic system—the one constant is change. This is demonstrated daily by hydrothermal activity ...
The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic ...
Discover how Caldera International is transforming pet care with innovative heated and therapeutic solutions for improved comfort and health. CANBY, OR, UNITED STATES, January 6, 2026 ...